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Using a Systems Pharmacology Approach to Study the
Effect of Statins on the Early Stage of Atherosclerosis
in Humans
C Pichardo–Almarza1,2*, L Metcalf1, A Finkelstein3 and V Diaz-Zuccarini1
More than 100,000 people have participated in controlled trials of statins (lowering cholesterol drugs) since the introduction of
lovastatin in the 1980s. Meta-analyses of this data have shown that statins have a beneficial effect on treated groups
compared to control groups, reducing cardiovascular risk. Inhibiting the HMG-CoA reductase in the liver, statins can reduce
cholesterol levels, thus reducing LDL levels in circulation. Published data from intravascular ultrasound studies (IVUS) was
used in this work to develop and validate a unique integrative system model; this consisted of analyzing control groups from
two randomized controlled statins trials (24/97 subjects respectively), one treated group (40 subjects, simvastatin trial), and 27
male subjects (simvastatin, pharmacokinetic study). The model allows to simulate the pharmacokinetics of statins and its
effect on the dynamics of lipoproteins (e.g., LDL) and the inflammatory pathway while simultaneously exploring the effect of
flow-related variables (e.g., wall shear stress) on atherosclerosis progression.
CPT Pharmacometrics Syst. Pharmacol. (2015) 4, e7; doi:10.1002/psp4.7; published online on 30 December 2014.
Absorption and metabolism of statins in humans have been
analyzed using conventional pharmacokinetic and pharma-
codynamic (PKPD) modeling approaches.1 The compre-
hensive, systematic and quantitative analysis of
atherosclerosis formation is becoming essential now that
patients are consistently treated with statins; particularly in
the light of controversies over their benefit/detriment ratio
(http://www.medscape.com/viewarticle/825246). Existing mod-
els can be improved by adding new mechanisms, and by pro-
viding a better description of the physiology and the PKPD
properties of the drug. A systems pharmacology approach,
aiming to provide a better model combining PKPD and sys-
tems biology, allows us to develop models containing more
information about the dynamic interaction between a drug
and a biological system so as to understand the behavior of
the system as a whole, as opposed to the behavior of its indi-
vidual components.2 As highlighted by Van der Graaf and
Benson,2 systems pharmacology is expected to have an
impact across all stages of drug research and development,
ranging from very early discovery programs to large-scale
Phase 3/4 patient studies. Our aim is to use the model pro-
posed in this work to demonstrate how a “systems approach”
can be used to develop a new model of atherosclerosis
where mechanisms from different physical domains and bio-
logical scales can be combined with the PKPD properties of
statins (i.e., simvastatin), with the objective to show plaque
growth in a synthetic population using this approach and
to compare this with well-known studies, for validation
purposes.
Mathematical models of atherosclerosis
Mathematical models of atherosclerosis pose a particular
challenge in that they require the description of multiple
physical (mechanical, biochemical, etc.), time-varying proc-
esses and mechanisms at multiple scales, i.e., from the
physiological (i.e., blood hemodynamics) to nanoscale
mechanisms in the arterial wall.3 One hypothesis, sup-
ported in the literature, is that mechanical factors such as
wall shear stress, pulsatile blood flow, and vessel curvature
are a trigger for the disease. This has been described in
several models.4–6 In particular, wall shear stress (WSS)
has been identified as one of the main hemodynamic fac-
tors determining endothelial dysfunction.7 Turbulence and
flow detachment can be associated with the location of
atherosclerotic plaque. The plaque specially affects
“predisposed” areas of the blood vessel such as bifurca-
tions or zones with flow recirculation, where the shear
stresses are low. WSS lower than 0.4 Pa (approx.) stimu-
lates an atherogenic phenotype and eases atherosclerotic
lesion initiation.7 Conversely, literature also suggests an
association between high shear stress values (i.e., greater
than 1.5 Pa), endothelial quiescence, and atheroprotective
gene expression.7
One key assumption in the modeling literature is that the
main cause of plaque development is the abnormal enlarge-
ment of the intima by the infiltration and accumulation within
the arterial wall of macromolecules such as lipoproteins, i.e.,
low density lipoprotein (LDL).8 Therefore, zones with high LDL
values (which are zones likely to have pro-atherogenic WSS
values) are considered to contribute to the development of the
atherosclerotic lesion and intimal thickening. Additional mecha-
nisms related to the recruitment of monocytes from the circu-
lation (in response to inflammatory mediators) and their
differentiation to macrophages to produce foam cells9 are also
considered to model the formation of the fatty streaks.
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The transport of macromolecules through the endothe-
lium has been modeled previously considering two main
pathways: transport through vesicular transcytosis (regu-
lated by receptors on the endothelial cells)10 and transport
through leaky and normal junctions, most of which are
located at the sites of dying or replicating cells.11
A number of computational models have been proposed
in the literature; for example, Cobbold12 and Gessaghi
et al.13 modeled the oxidation process of LDL considering
the action of different vitamins such as vitamin E in the
LDL oxidation process. Di Tomaso et al.14 used a similar
approach to model LDL oxidation coupled with a fluid
dynamics model of the artery. Zohdi et al.15 considered the
endothelial monocyte adhesion controlled by blood flow
conditions and its influence on the inflammation process.
Fok16 modeled the intimal thickening considering the
release of cytokines and the migration of smooth muscle
cells. Siogkas et al.17 used a similar approach including the
dynamics of oxidized LDL, macrophages, and cytokines.
A similar model from Calvez et al.18 included the formation
of foam cells. Ougrinovskaia et al.19 explored the uptake of
cholesterol by different scavenger receptors of macrophages
during early stage atherosclerosis. Bulelzai and Dubbel-
dam20 developed a simplified model for the dynamics of the
main components of the atherosclerotic plaque: macro-
phages, monocytes, foam cell, and oxidized LDL. Chung
and Vafai21 described the atheroma based on the LDL trans-
port and how this was affected by fluid–structure interaction
and pulsation. More recently Cilla et al.22 compiled and inte-
grated several of the previous approaches in order to build a
new model of atherosclerosis, including the species playing
a main role in early development of the plaque, i.e., LDL,
oxidized LDL, monocytes, macrophages, foam cells, smooth
muscle cells, cytokines, and collagen.
The model presented in this work uses some of the
assumptions from prior models, as explained below in the
Methods section.
Statins
Statins (e.g., Simvastatin) are a HMG-CoA (3-hydroxy-3-
methylglutaryl-coenzyme A) reductase inhibitor effective in
the treatment of hypercholesterolemia and hypertriglyceri-
daemia.23 They have been widely prescribed to reduce the
risk of cardiovascular morbidity and mortality24 and throm-
boembolic stroke in high-risk patients.25,26 After oral admin-
istration, simvastatin is rapidly absorbed (max of 1–2 h)27,28
and eliminated. Once administered, simvastatin rapidly
undergoes reversible nonenzymatic or carboxylesterase-
mediated conversion to its active metabolite, simvastatin
acid, in the liver, intestinal mucosa, and plasma.23,29 Simva-
statin acid prevents HMG-CoA reductase from converting
HMG-CoA to mevalonate, which is a rate-limiting step in
cholesterol biosynthesis.30 Inhibition of the HMG-CoA
reductase in the liver results in the reduction in cholesterol
synthesis. Moreover, the up-regulation of LDL receptors
located on the cell membranes of the liver and extrahepatic
tissues thereby also contribute to the reduction in plasma
LDL concentrations.31
Given the beneficial effects of statins in humans, the aim
of this work is the development of a new integrative system
model to yield a better understanding of the dynamics of
the inflammatory mechanisms related to the early stages of
atherosclerosis. Our model provides an account of the
behavior of lipoprotein levels (e.g., LDL), the mechanical
and flow properties inside the arterial lumen (e.g., wall
shear stress), and the mechanisms of the effect of choles-
terol lowering drugs (e.g., statins) on the progression of the
atherosclerotic plaque.
RESULTS
The integrative model used in this work is the product of
combining several approaches and temporal data related to
the progression of the atherosclerotic lesion and the effect
of statins inhibiting the development of the plaque. The final
outcome shows the dynamic behavior of the plaque size,
which has an effect on all the components of this model,
mainly because species concentrations in the lumen and
the arterial wall (and the WSS) are affected by changes in
the arterial wall (see Figure 1a). Four main aspects were
considered and combined to describe all these mecha-
nisms and interactions: (1) blood flow and mechanical prop-
erties of the artery; (2) transport of macromolecules and
immune cells through the endothelium; (3) administration,
metabolism, and pharmacological effect of statins; (4) anal-
ysis and comparison of clinical trials.
Figure 2a illustrates the behavior of the model when
there is no drug present in the system. The black line is the
median of %TAV for the synthetic population. The dotted
red and blue lines show a projection of the trends using the
growth rates reported in ESTABLISH33 and ENCORE II34
studies (see Supplementary Materials S1, available online).
Using the parameter values proposed in this work, the 5th
and the 95th percentile of the simulated values are between
the boundary values of growth imposed by the data esti-
mated from these clinical trials. It is possible to increase
the variability of this variable (%TAV) expanding the varia-
tion range of the parameters and/or using a smaller syn-
thetic population (< 1,000 individuals).
The simulated response curve of simvastatin and simva-
statin acid for the first 96 h (four administrations) are shown
in Figure 2b. According to the measurements of Kim
et al.,1 the half-life of simvastatin is relatively short (2–5 h),
in fact plasma concentration of simvastatin is eliminated in
2 d after single administration1 (not shown in Figure 2b
due to the daily dose regimen).
The simulated LDL concentrations, however, continued to
decrease when a multiple dose is applied (Figure 2c). Sim-
ilar results have been described in the label of ZOCOR
(http://www.merck.com/product/usa/pi_circulars/z/zocor/
zocor_pi.pdf) and another simvastatin study reported by
Law et al.26
Figure 2d illustrates the comparison of the simulation
results of the proposed integrative model with the growing
trends obtained from the study by Jensen et al.32 The
decrease of LDL in the circulation due to the effect of sim-
vastatin produced a decrease on the amount of LDL enter-
ing the wall and the production of foam cells leading to a
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decrease on the plaque rate of growth, as shown in Figure
2d.
Furthermore, the model shows the effects of blood flow
on the initiation and development of atherosclerotic plaque.
Changes in lumen diameter owing to plaque growth will
influence the pattern of blood flow, and therefore WSS,35
with the endothelial cells responding to signals induced by
WSS.35,36 Therefore, the low shear stress region of the pla-
que will remain atheroprone.
METHODS
Mathematical modeling of atherosclerosis
The mathematical model presented here is based upon the
hypothesis that the atherosclerosis process begins with the
entry of LDL into the intima of the vessel,39 where it oxi-
dizes, starting the inflammatory process: monocytes first
adhere to the endothelium, and then penetrate into the
intima, where they differentiate into macrophages (see Fig-
ure 1b).
The secretion of pro-inflammatory cytokines (due to a
chronic inflammatory response) promotes the recruitment
of monocytes from the circulation, which differentiate to
macrophages in the arterial wall. Macrophages uptake of
oxidized LDL (ox-LDL) leads to the formation of foam cells,
which in turn may be removed by the immune system.
This model (described in words above) is conceptually
divided in two main parts: a “biochemical” model describing
the LDL oxidation and the immune response (e.g., effect of
pro and anti-inflammatory cytokines); and a “mechanical”
model describing the plaque growth and the effect of blood
flow conditions on the evolution of the plaque. The athero-
sclerotic lesion, comprising fibrous cap and lipid deposit,
changes the internal geometry of the vessel (lumen) and
interacts with the blood flow. This interaction may lead to a
thrombus, or to the degradation and rupture of the pla-
que.40 In this model, low shear stress is associated with
plaque location, given some evidence suggesting that shear
stress may act through endothelial gene expression or by a
process of localized inflammation.41 A simplified diagram of
the processes described by this mathematical model is
shown in Figure 1b.
Modeling the hemodynamics, endothelial behavior, and
WSS. Capturing the dynamics of the blood flow is funda-
mental as atherosclerotic-prone areas are associated with
regions of low shear stress due to their impact on endothe-
lium behavior as previously mentioned. The hemodynamics
are calculated using the continuity (1) and Navier-Stokes
equations (2).
@q
@t
1r  q Uð Þ50 (1)
@ q Uð Þ
@t
52rp1r  sij1qg (2)
where p is the pressure, s is the shear stress tensor, q is
the density, and U is the flow velocity.
Local flow conditions near the wall can significantly
enhance or impede the transport of molecules from the
lumen to the arterial wall and are typically characterized by
the WSS. For fully developed, laminar flow through a rigid
tube and using Poiseuille law, s can be calculated as a
Figure 1 (a) Simplified diagram of the integrative systems model
proposed. (b) Fatty streak formation: Main mechanisms considered
in the atherosclerosis model. (c) Simplified diagram of the athero-
sclerosis model showing variables and kinetic rate constants.
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function of the volumetric flow rate (Q), the viscosity of the
blood (l), and the vessel radius (r)42 as follows:
s5
4 l Q
p r 3
: (3)
Membrane-transport model. The LDL flux across the endo-
thelium was modeled using Kedem Katchalsky’s equations,
as below.
Jv5LpðDp2rDPÞ (4)
Js5P0Dc1Jv 12rð ÞJv c (5)
where Jv is the transmural velocity and Js is the solute flux
through the endothelium, Lp is the hydraulic conductivity,
Dp and DP are the pressure difference and the osmotic
pressure difference across the endothelial membranes,
respectively, P0 is the diffusive endothelial permeability, Dc
is the solute concentration, c is the mean endothelial con-
centration, r is the reflection coefficient. The osmotic pres-
sure difference was neglected to decouple the fluid
dynamics from solute dynamics.43,44 It is assumed that the
hydraulic conductivity depends on the shear stress (3) at
the wall (WSS), using the following equation45:
LpðjWSSjÞ50:3881310212lnðjWSSj10:015Þ12:7656310212 (6)
where |WSS| is the absolute value of WSS. This relation-
ship between WSS and Lp shows that the endothelium per-
meability to blood macromolecules increases when subject
to higher WSS. The hemodynamic stimulus on endothelial
cells is mediated by mechanoreceptors linked to critical sig-
naling pathways (e.g., NO-dependent mechanisms) and
involves the conversion of the biomechanical stimuli to bio-
chemical responses. In this context, the above relationship
Figure 2 (a) Comparison of simulation results (%TAV - 10 years of plaque growth) with growth trends reported in literature for control
groups. (b) PK of simvastatin and simvastatin acid using the pharmacokinetics/pharmacodynamics (PKPD) model proposed. (c) LDL
dynamic response to a daily dose of 40 mg of simvastatin during 12 months. (d) Comparison of simulation results for the plaque
growth (%TAV) with the Jensen et al.32 study. In panel (a), time5 0 months is the time when the plaque starts to grow. In panels (b–d),
time5 0 months is the time when the therapy starts.
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incorporates into the simulation the effect of WSS on cellu-
lar processes that result in the alteration of the pathways
governing the transendothelial transport of water and sol-
utes (e.g., intercellular junctions).46,47
An additional relationship between the diffusive perme-
ability and LDL concentration was proposed by Sakellarios
et al.45 on the basis of experimental data reported by Gur-
etzki et al.48 (Eq. 7):
P052:4660310
12e2641c1 (7)
where c1 is the local LDL concentration on the luminal side
of the endothelium. Using this equation, the LDL endothelial
penetration depends on WSS as well as the magnitude of
the lumen concentration.
Atherogenesis as a transport process inside the arterial
wall. The intima, media, internal elastic lamina, and exter-
nal elastic lamina were considered as forming one single
layer. The results shown in this article are from a simplified
version of the model where the arterial wall is considered a
well-stirred volume, given that results of the spatial distribu-
tion of the different species in the wall (e.g., LDL, foam
cells, etc.) are out of the scope of this work. In general, ath-
erosclerosis models use a convection-diffusion-reaction
equation to describe the transport of LDL (Lw) from the
arterial lumen to the arterial wall (see for example the
model from Di Tomaso et al.14):
dLw
dt
52uw  rLw1DwDLw2rwLw (8)
where uw is the transmural velocity and Dw is the diffusivity
of LDL in the wall. The last term of Eq. 8 represents the
oxidation of LDL, where rw is the reaction rate constant.
The oxidized LDL (Lox) is then expressed as:
dLox
dt
5rwLw2dlox Lox (9)
The transport of monocytes in the arterial wall (mw) is
controlled by Lox and the concentration of monocytes in the
lumen (mlumen) (assumed constant for this first modeling
approach). This is calculated using a similar relationship to
the one proposed by Bulelzai and Dubbeldam20 and Cilla
et al.22:
dmw
dt
5C WSS; Loxð Þmlumen2dmmw2q1mw (10)
C WSS; Loxð Þ5 c011WSS=WSS0
Lox (11)
where q1 is the rate constant for the differentiation of mono-
cytes into macrophages. The value of WSS0 designates the
wall shear stress at which the growth rate of the monocyte
concentration due to the signaling response by the endo-
thelium is reduced with a factor of two compared to the
zero wall shear rate response by the endothelium. The fac-
tor c0 is a constant determining the rate at which mono-
cytes enter the intima for low wall shear stress and low Lox.
Finally, the dynamic equations of the macrophages (Mw)
and the formation of foam cells (Fw) due to the macrophage
uptake of oxidized LDL (Lox) inside the arterial wall are:
dMw
dt
5q1mw2kmLoxMw2dMMw (12)
dFw
dt
5kmLoxMw2dFFw (13)
where dlox, dm, dM, and dF are rate constants for oxidized
LDL, monocytes, macrophages, and foam cell diffusion out
of the plaque respectively.
To simulate the formation of the initial stages of the pla-
que, it was assumed that a narrowing of the lumen would
occur if the volume covered by all the cells considered is
larger than the initial arterial volume (Figure 3a). Please
note that foam cells are key for the remodeling of the arte-
rial wall.
The volume of the plaque (i.e., intima plus media layers)
is then calculated as the sum of the volumes occupied by
the different species (i.e., foam cells, macrophages, mono-
cytes, LDL) inside the wall.
PKPD model of statins
The PKPD model used in this work is based on the model
published by Kim et al.1 The model used well stirred com-
partments (assuming that the mixing rates are shorter than
the reaction rates) and was developed using data collected
from 27 healthy male volunteers with a daily dose of 40 mg
of simvastatin given for 14 d. Simvastatin lactone (parent
drug) and simvastatin acid (metabolite) plasma concentra-
tions were measured at 0, 0.5, 1, 1.5, 2, 3, 3.5, 4, 5, 6, 8,
10, 12, and 24 h after the dose on days 1, 7, and 14. LDL
concentrations were measured daily after an overnight fast.
The PK model is a parent/metabolite model with first-
order absorption and elimination as this configuration pro-
vided the best fit for the pharmacokinetic data. The PD
model is based on the effect of simvastatin on LDL concen-
tration using an inhibitory turnover model with the metabo-
lite, simvastatin acid, as the driver (Figure 4). Table 1
summarizes the population parameter estimates for this
model and published by Kim et al.1
The two-compartment model shown in Figure 4 tries to
reproduce the temporal data related to the absorption and
metabolism of the drug (in this case, simvastatin), its phar-
macological effect on the production of cholesterol by the
liver and the availability of LDL in circulation. The mathe-
matical equations to describe these mechanisms are
ordinary differential equations related to a standard
two-compartment PKPD model.1
Clinical trials and assessment of the atheroma
burden
IVUS studies were selected to evaluate the effect of statins
in the progression of the atheroma size. IVUS is a medical
imaging methodology using a catheter with a miniaturized
ultrasound probe attached that provides high-resolution
information about the arterial lumen and wall. Figure 3b
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shows how IVUS are used to estimate the volume of the
plaque.
The results of the control groups reported in the ESTAB-
LISH33 and ENCORE II34 trials were used to compare with
the results of the integrative model when there is no drug
in the system.
The results of plaque growth under the effect of simvastatin
reported by Jensen et al.32 were used to compare the results
of the integrative model in the presence of the drug. A brief
summary of the results from these trials is shown in Table 2.
The atheroma or plaque area in cross-sectional IVUS
images was calculated by subtracting the lumen area from
the external elastic membrane area (see Figure 3b).
Hence, an IVUS-defined atheroma area is a combination of
plaque plus media area. The atheroma area is calculated in
each frame (cross-sectional image), and total atheroma vol-
ume (TAV) (Eq. 14) can be calculated based on the pull-
back speed during imaging acquisition. Then, the change
of the atheroma volume can be reported as a percentage
of the initial volume of the external elastic membrane occu-
pied by atheroma, called in our case %TAV (Eq. 15). (The
reader is referred to the work by Garcia-Garcia et al.50 for
more details about these methods.)
TAV5EEM2LUMEN cross-sectional areað Þ (14)
%TAV5
TAV2TAVbaseline
TAVbaseline
3100 cross-sectional areað Þ: (15)
These equations give an estimation of the changes of
%TAV that can be compared with the simulation results
from the model proposed.
Simulations: synthetic population
As an illustrative example for this article a synthetic pop-
ulation was built in order to evaluate how the simulations
behave with respect to the variability of some parameters
between individuals. Simulations were generated with
Matlab (http://www.mathworks.com) using the ode15s
solver (Supplementary Materials S2 includes more details
about the computational implementation of this model).
The population is composed of 1,000 subjects. Based on
the data available, a minimal set of parameters was varied
Figure 3 (a) “Growth” as implemented in the model. The arterial lumen (in red) would be remodeled as a consequence of plaque for-
mation and development in time (in yellow). (b) Method for analysis of atheroma area. The left panel shows a representative intravas-
cular ultrasound cross section. The right panel illustrates the boundaries planimetered for the external elastic membrane (EEM) and
lumen and how the atheroma area is calculated. Image published by Nicholls et al.49 Copyright Elsevier (2006).
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in order to produce individual variations. Three model
parameters were selected considering they were log-normal
distributed across the population. They were the LDL con-
centration in blood, the blood viscosity, and the radius of the
artery, parameters that are expected to show some variabili-
ty in clinical studies, however, additional parameters (i.e.,
kinetic rate constants) might be included in future simula-
tions in order to include additional intervariability between
Table 1 Systems pharmacology model: parameter values
Symbol Quantity Value
Model of atherosclerosis
km (m
3 cells21 s21) Foam cell formation constant22 9.25 3 10224
dm (s
21) Diffusion of monocytes out of the plaque20 5.75 3 1026
dlox (s
21) Diffusion of LDL out of the plaque20 2.4 3 1025
dM (s
21) Diffusion of macrophages out of the plaquea 5.75 3 1026
dF (s
21) Diffusion of foam cells out of the plaquea 5.75 3 1026
rw (s
21) LDL oxidation rate constant14 3 31024
m (Pa s) Blood viscosity20 0.004
WSS0 (Pa) WSS threshold for monocyte wall transport
20 1
q1 (s
21) Rate of differentiation of monocytes into macrophages20 1.15 3 1026
r0 (dm) Initial lumen radius 0.03
c0 (m
3 nmol21 day21) Rate constant in Eq. 1122 5.5 3 10213
Dp (Pa) Endothelial pressure difference22 2400
Q (l/s) Blood flow 0.0075
mlumen (cells/l) Concentration of monocytes in blood
22 5.5 3 108
r Endothelial reflection coefficient45 0.997
PKPD Model
CL2(L/hr) Clearance compartment 2 1740
V2(L) Volume compartment 2 8980
CL3(L/hr) Clearance compartment 3 383
V3 (L) Volume compartment 3 1190
Ka (1/hr) Absorption rate constant 2.76
Kin (nmol/L/hr) Production rate of LDL 29.52
Emax Max. effect due to the drug 0.489
EC50 (ng/ml) Blood concentration at half max. effect 0.0868
LDLbaseline (nmol/L) Baseline LDL 1400
Kout Elimination rate constant for LDL Kin/LDLbaseline
aValue proposed for this model.
Figure 4 Diagram of the pharmacokinetics/pharmacodynamics (PKPD) model used in this work and proposed by Kim et al.1
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patients, although in that case additional data (i.e., more
complex measurements and experiments related to the
kinetic rates) might be needed.
Table 3 summarizes the statistical details of these
parameters used for the simulations.
DISCUSSION
Results of the coupling between the PKPD model and the
more detailed model of the artery shows the effect of sta-
tins on several mechanisms related to plaque growth,
beyond the effect that statins have shown lowering LDL val-
ues in circulation. A comparison with the results reported
by Jensen et al.32 (Figure 2d) has shown how this type of
systems model can be calibrated in order to reproduce the
dynamic response of the plaque growth for a given popula-
tion treated with simvastatin.
Simulation results allow us to conclude that new integra-
tive models can be developed combining information and
data from different sources in order to achieve a holistic
understanding of the process of atherosclerosis and the
effect of statins. The model presented in this paper is mod-
ular, meaning that specific parts of the model (modules)
were developed to describe specific mechanisms, i.e., a
module to describe blood flow, another module to describe
LDL dynamics and oxidation, another module to describe
immune response, and another module to describe statin
administration, metabolism, and pharmacological effect.
The main advantage of this approach is that each individual
module can be improved (for example, by adding more
mechanisms based on new evidence or data) or simplified
being the ultimate goal the validation of all the biological/
physiological scales considered in this type of model. More
specifically, future changes in the PKPD module to improve
the whole model might consider:
1. Modeling the effect of circadian rhythms on the LDL levels as pro-
posed by Wright et al.37
2. The inclusion of the pleiotropic effect of statins, using a similar
approach to that proposed by Rose et al.38 (modifying the PK
model proposed here)
3. Studying the effect of statins on the upregulation of hepatic LDL
receptors
Here, an analysis based on the effects of simvastatin
was made, however other cholesterol-lowering drugs could
also be considered using the same approach just by chang-
ing the PKPD properties.
The absorption and metabolism of statins in humans have
been analyzed before using conventional pharmacokinetics
and pharmacodynamics (PKPD) modeling approaches.1 Our
work has shown that these models can be improved adding
new mechanisms and providing a better description of the
physiology and the PKPD properties of the drug. A systems
pharmacology approach was applied, combining PKPD and
physiological modeling based on mass transport and fluid
dynamics, giving more information about the dynamic inter-
action of different elements of the atherosclerotic plaque and
the drug. The model showed how a systems pharmacology
approach can be used to develop a new model of atheroscle-
rosis where mechanisms from different physical domains and
biological scales can be combined with the PKPD properties
of statins (i.e., simvastatin).
It is important to mention that the upregulation of LDL
receptors in hepatocytes is not included in this model. The
model focuses on the plaque formation process, inside the
arterial wall, with LDL as the main trigger for the atherosclerotic
process to occur (cause-effect relationship). In this case, the
effect of statins as a way to decrease LDL levels is explored.
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Table 2 Intravascular ultrasound progression/regression studies
Study Type Year Treatment n (subjects) Follow-up (months) % Change of TAV
ESTABLISH33 RCT 2004 Atorvastatin 24 6 13.1%
Control 24 8.7%
ENCORE II34 RCT 2009 Nifedipine 97 18–24 5.0%
Placebo 96 3.2%
Jensen et al.32 Non-RCT 2004 Simvastatin 40 12 6.3%
RCT, randomized controlled trial.
Table 3 Parameter values for the synthetic population
LDL levels in blood:
Mean5 1402 nmol/l
Median51396 nmol/l
Standard deviation5 141
5th and 95th percentile5 (1190 – 1644)
Blood viscosity:
Mean5 0.004 Pa s
Median50.004 Pa s
Standard deviation5 8e-5
5th and 95th percentile5 (0.0039 – 0.0041)
Lumen radius:
Mean5 0.03 dm
Median50.03 dm
Standard deviation5 0.0015
5th and 95th percentile5 (0.0277 – 0.0325)
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Prior research has studied statins using standard PKPD
modeling approaches. There are currently no models in
the literature coupling the PK properties of statins and
their effect on the atherosclerosis inflammatory mecha-
nisms and mechanical properties in arteries.
WHAT QUESTION DID THIS STUDY ADDRESS?
We seek to improve the collective understanding of the
effect of cholesterol-lowering drugs in the development
of plaque by using a novel modeling approach able to
capture mechanistically, the relationships between the
drug and a physiological representation of the artery.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Data on lipid metabolism and atherosclerosis is increas-
ingly available and further experimental and clinical stud-
ies are anticipated. The systems model proposed here
shows how clinical trials data can be combined with
mechanistic models of atherosclerosis.
HOW THIS MIGHT CHANGE CLINICAL
PHARMACOLOGY AND THERAPEUTICS
 This kind of integrative approach permits the study of the
effect of statins beyond lowering cholesterol levels in
the circulation. Computational simulations can test differ-
ent pharmacological or physiological hypotheses on ath-
erosclerosis progression, with potential benefits to health
outcomes.
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